193 related articles for article (PubMed ID: 19202074)
1. Transforming activity of AML1-ETO is independent of CBFbeta and ETO interaction but requires formation of homo-oligomeric complexes.
Kwok C; Zeisig BB; Qiu J; Dong S; So CW
Proc Natl Acad Sci U S A; 2009 Feb; 106(8):2853-8. PubMed ID: 19202074
[TBL] [Abstract][Full Text] [Related]
2. CBFbeta is critical for AML1-ETO and TEL-AML1 activity.
Roudaia L; Cheney MD; Manuylova E; Chen W; Morrow M; Park S; Lee CT; Kaur P; Williams O; Bushweller JH; Speck NA
Blood; 2009 Mar; 113(13):3070-9. PubMed ID: 19179469
[TBL] [Abstract][Full Text] [Related]
3. Heterodimerization of AML1/ETO with CBFβ is required for leukemogenesis but not for myeloproliferation.
Thiel VN; Giaimo BD; Schwarz P; Soller K; Vas V; Bartkuhn M; Blätte TJ; Döhner K; Bullinger L; Borggrefe T; Geiger H; Oswald F
Leukemia; 2017 Nov; 31(11):2491-2502. PubMed ID: 28360416
[TBL] [Abstract][Full Text] [Related]
4. The AML1/ETO(MTG8) and AML1/Evi-1 leukemia-associated chimeric oncoproteins accumulate PEBP2beta(CBFbeta) in the nucleus more efficiently than wild-type AML1.
Tanaka K; Tanaka T; Kurokawa M; Imai Y; Ogawa S; Mitani K; Yazaki Y; Hirai H
Blood; 1998 Mar; 91(5):1688-99. PubMed ID: 9473235
[TBL] [Abstract][Full Text] [Related]
5. Dominant negative effects of the AML1/ETO fusion oncoprotein.
Fenske TS; Pengue G; Graubert TA
Cell Cycle; 2005 Jan; 4(1):33-6. PubMed ID: 15611635
[TBL] [Abstract][Full Text] [Related]
6. A stable transcription factor complex nucleated by oligomeric AML1-ETO controls leukaemogenesis.
Sun XJ; Wang Z; Wang L; Jiang Y; Kost N; Soong TD; Chen WY; Tang Z; Nakadai T; Elemento O; Fischle W; Melnick A; Patel DJ; Nimer SD; Roeder RG
Nature; 2013 Aug; 500(7460):93-7. PubMed ID: 23812588
[TBL] [Abstract][Full Text] [Related]
7. RUNX1/AML1 DNA-binding domain and ETO/MTG8 NHR2-dimerization domain are critical to AML1-ETO9a leukemogenesis.
Yan M; Ahn EY; Hiebert SW; Zhang DE
Blood; 2009 Jan; 113(4):883-6. PubMed ID: 19036704
[TBL] [Abstract][Full Text] [Related]
8. AML-1-ETO-Mediated erythroid inhibition: new paradigms for differentiation blockade by a leukemic fusion protein.
Choi Y; Elagib KE; Goldfarb AN
Crit Rev Eukaryot Gene Expr; 2005; 15(3):207-16. PubMed ID: 16390317
[TBL] [Abstract][Full Text] [Related]
9. An AML1-ETO/miR-29b-1 regulatory circuit modulates phenotypic properties of acute myeloid leukemia cells.
Zaidi SK; Perez AW; White ES; Lian JB; Stein JL; Stein GS
Oncotarget; 2017 Jun; 8(25):39994-40005. PubMed ID: 28611288
[TBL] [Abstract][Full Text] [Related]
10. Attenuation of AML1-ETO cellular dysregulation correlates with increased leukemogenic potential.
DeKelver RC; Yan M; Ahn EY; Shia WJ; Speck NA; Zhang DE
Blood; 2013 May; 121(18):3714-7. PubMed ID: 23426948
[TBL] [Abstract][Full Text] [Related]
11. Proleukemic RUNX1 and CBFbeta mutations in the pathogenesis of acute leukemia.
Engel ME; Hiebert SW
Cancer Treat Res; 2010; 145():127-47. PubMed ID: 20306249
[TBL] [Abstract][Full Text] [Related]
12. The p21Waf1 pathway is involved in blocking leukemogenesis by the t(8;21) fusion protein AML1-ETO.
Peterson LF; Yan M; Zhang DE
Blood; 2007 May; 109(10):4392-8. PubMed ID: 17284535
[TBL] [Abstract][Full Text] [Related]
13. Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia.
Higuchi M; O'Brien D; Kumaravelu P; Lenny N; Yeoh EJ; Downing JR
Cancer Cell; 2002 Feb; 1(1):63-74. PubMed ID: 12086889
[TBL] [Abstract][Full Text] [Related]
14. Supraphysiologic levels of the AML1-ETO isoform AE9a are essential for transformation.
Link KA; Lin S; Shrestha M; Bowman M; Wunderlich M; Bloomfield CD; Huang G; Mulloy JC
Proc Natl Acad Sci U S A; 2016 Aug; 113(32):9075-80. PubMed ID: 27457952
[TBL] [Abstract][Full Text] [Related]
15. The leukemogenic t(8;21) fusion protein AML1-ETO controls rRNA genes and associates with nucleolar-organizing regions at mitotic chromosomes.
Bakshi R; Zaidi SK; Pande S; Hassan MQ; Young DW; Montecino M; Lian JB; van Wijnen AJ; Stein JL; Stein GS
J Cell Sci; 2008 Dec; 121(Pt 23):3981-90. PubMed ID: 19001502
[TBL] [Abstract][Full Text] [Related]
16. ETO and AML1 phosphoproteins are expressed in CD34+ hematopoietic progenitors: implications for t(8;21) leukemogenesis and monitoring residual disease.
Erickson PF; Dessev G; Lasher RS; Philips G; Robinson M; Drabkin HA
Blood; 1996 Sep; 88(5):1813-23. PubMed ID: 8781439
[TBL] [Abstract][Full Text] [Related]
17. The Hematopoietic Transcription Factors RUNX1 and ERG Prevent AML1-ETO Oncogene Overexpression and Onset of the Apoptosis Program in t(8;21) AMLs.
Mandoli A; Singh AA; Prange KHM; Tijchon E; Oerlemans M; Dirks R; Ter Huurne M; Wierenga ATJ; Janssen-Megens EM; Berentsen K; Sharifi N; Kim B; Matarese F; Nguyen LN; Hubner NC; Rao NA; van den Akker E; Altucci L; Vellenga E; Stunnenberg HG; Martens JHA
Cell Rep; 2016 Nov; 17(8):2087-2100. PubMed ID: 27851970
[TBL] [Abstract][Full Text] [Related]
18. Compatibility of RUNX1/ETO fusion protein modules driving CD34+ human progenitor cell expansion.
Chen-Wichmann L; Shvartsman M; Preiss C; Hockings C; Windisch R; Redondo Monte E; Leubolt G; Spiekermann K; Lausen J; Brendel C; Grez M; Greif PA; Wichmann C
Oncogene; 2019 Jan; 38(2):261-272. PubMed ID: 30093631
[TBL] [Abstract][Full Text] [Related]
19. The acute myeloid leukemia associated AML1-ETO fusion protein alters the transcriptome and cellular progression in a single-oncogene expressing in vitro induced pluripotent stem cell based granulocyte differentiation model.
Tijchon E; Yi G; Mandoli A; Smits JGA; Ferrari F; Heuts BMH; Wijnen F; Kim B; Janssen-Megens EM; Schuringa JJ; Martens JHA
PLoS One; 2019; 14(12):e0226435. PubMed ID: 31869378
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of the transforming growth factor beta 1 signaling pathway by the AML1/ETO leukemia-associated fusion protein.
Jakubowiak A; Pouponnot C; Berguido F; Frank R; Mao S; Massague J; Nimer SD
J Biol Chem; 2000 Dec; 275(51):40282-7. PubMed ID: 11032826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
